Compare Icl Group Ltd (ICL) vs Revolution Medicines Inc. Common Stock (RVMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Revolution Medicines Inc. Common Stock — how do they compare? Icl Group Ltd trades at $5.02 (market cap $6.47B), while Revolution Medicines Inc. Common Stock trades at $189.76 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 6.2× Icl Group Ltd's market cap, and Icl Group Ltd pays a 4.11% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| ICL | RVMD | |
|---|---|---|
Market Cap | $6.47B | $40.32B |
Volume | 1,387,140 | 4,855,734 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $221.15 |
52-Week Low | $4.80 | $47.50 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $9.11B | $37.02B |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.00, down 1.57% today, with a bearish technical signal from moving averages but a neutral oscillator stance. Recent earnings beat estimates in Q1 and Q2 2026, though revenue and net income have trended lower from 2022 peaks. The company maintains a dividend, with a $0.06 payment scheduled for September 2026, and operates with stable cash flow from operations around $1.1 billion.
The outlook is mixed: valuation ratios like P/E of 20.83 and P/S of 0.84 suggest reasonable pricing, but analyst consensus is entirely Hold with a $6.08 target. Risks include industry headwinds from higher input costs and competitive pressures, while institutional buying, like Amundi's Q1 2026 purchase, offers support. Earnings growth and cost transformation are key to upside.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →
